22 results about "Soft tissue sarcoma" patented technology

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

A combination therapy for the treatment of cancer, particularly soft tissue sarcoma, is described, which includes low doses of lurbinectedin and doxorubicin.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

Provided herein are methods and compositions for treating cancer. In some cases, the cancer comprises soft tissue sarcoma, such as synovial sarcoma. In some cases, the treatment comprises administering a therapeutically effective amount of an SS18-SSX fusion protein inhibitor to the subject. In some cases, the treatment comprises administering a therapeutically effective amount of SUMO2 inhibitor to the subject. The subject can be a pediatric subject or an adult subject.

The application provides a preparation method and application of a bone and soft tissue sarcoma organoid. A bone and soft tissue sarcoma tissue sample is placed in a modified organoid culture medium and placed in a CO2 incubator for culture at 37 DEG C. Half of the medium is replaced every two days, and a bone and soft tissue sarcoma organoid can be obtained within two weeks. The method is simple to operate, significantly improves the survival rate and quantity of organoids, and shortens the culture time of organoids. Eight different subtypes of bone and soft tissue sarcoma organoids can be obtained by using the method. The bone and soft tissue sarcoma organoids obtained by the application can be passaged and stored at low temperature, retain all cell types of the original tumor tissue block, more truly simulate the tumor microenvironment, and provide more clinically consistent drug sensitivity test results. The bone and soft tissue sarcoma organoids obtained by the application can be used for personalized CAR-T treatment evaluation, drug sensitivity detection of chemotherapeutic drugs and targeted drugs, and preparation of personalized tumor vaccines.

The present invention relates to pharmaceutical compositions and methods for the treatment of carcinomas and sarcomas. In particular, the invention provides a pharmaceutical composition comprising a peptide or pharmaceutically acceptable salt thereof for use in treating a carcinoma or a sarcoma in a human subject, wherein the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1 and a cell penetrating peptide and wherein the pharmaceutical composition is systemically administered to the subject weekly to provide a dose of the peptide of about 15-65 mg / m2 body surface area (BSA) per week, calculated as the free form of the peptide.

The application relates to a preoperative risk scoring method for limb and trunk soft tissue sarcoma, which comprises the following steps: obtaining standardized MRI features of a patient, and classifying the standardized MRI features; and inputting the classification results of the standardized MRI features into a scoring model to obtain a preoperative risk score of the patient. The application can accurately evaluate the risk of limb and trunk soft tissue sarcoma non-invasively before operation by converting complex image information into a simple and understandable risk score through unified MRI feature definition and objective weight allocation, so as to provide a precise solution for preoperative planning and postoperative management of the patient.

The invention provides a dendritic cell vaccine for treating bone and soft tissue sarcoma as well as a preparation method and application of the dendritic cell vaccine. The dendritic cell vaccine comprises mature dendritic cells obtained by co-culturing sarcoma cell lysate and immature dendritic cells. The lysates of seven sarcoma cells are used as dendritic cell vaccine antigens, the problem that an existing DC vaccine is single in loaded antigen is solved, antigen presentation and T cell activation are enhanced, wide immune response is excited, immune escape is reduced, and the dendritic cell vaccine is not limited by the type of MHC of a patient, is high in universality and can benefit more patients.

A method for applying cold atmospheric plasma treatment to target tissue comprising the steps of treating a patient with a pharmaceutical for suppressing apolipoprotein E genes, selecting through a graphical user interface a particular soft tissue sarcoma cell line associated with target tissue, retrieving, with the computing device, settings data associated with the selected soft tissue sarcoma cell line from a database of cell line data and associated settings data in a storage, and applying, with the computing device, the retrieved settings data to a cold atmospheric plasma system.

This application relates, in certain embodiments, to a method and composition for treating soft tissue sarcomas (STS, e.g., spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma) using a composition comprising nanoparticles containing an mTOR inhibitor (e.g., limus drugs, e.g., sirolimus or its derivatives) and albumin in combination with a multityrosine kinase inhibitor (e.g., pazopanib).

The present invention belongs to the pharmaceutical field, and provides a quinoline derivative and antibody soft tissue sarcoma combination therapy, specifically relating to a use of a therapeutically effective amount of a quinoline derivative compound I or a pharmaceutically acceptable salt thereof in combination with at least one antibody drug in preparing a drug used for treating soft tissue sarcoma. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.

GD2-specific chimeric antigen receptor effector cells for the treatment of solid tumors, which can be combined with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor. ------ The present invention relates to GD2-specific chimeric antigen receptor (GD2.CAR) effector cells for the treatment of both solid tumors, particularly extracranial GD2+ tumors (such as soft tissue sarcomas and osteosarcomas, neuroblastomas, melanomas, lung cancers, bladder cancers, and retinoblastomas) and brain tumors. Furthermore, the present invention also relates to the use of GD2.CAR gene-modified effector cells in combination with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor in the treatment of solid tumors.

The present disclosure provides methods of treatment comprising anti-EDB antibodies and antibody-drug conjugates. The present disclosure further provides methods of treating EDB+ FN-expressing disorders, such as cancer. In some aspects, the method comprises administration of an anti-EDB+FN ADC to a patient having cancer, such as, for example, non-small cell lung cancer (NSCLC), breast cancer, head and neck cancer, ovarian cancer, thyroid cancer, pancreatic cancer, soft tissue sarcoma, chordoma, hepatocellular carcinoma, kidney cancer, cervical cancer, and endometrial cancer.

A quinoline derivative used for soft tissue sarcoma combination therapy, relating to a use of the quinoline derivative in combination with a second therapeutic drug to treat soft tissue sarcoma, wherein the second therapeutic drug may be a chemotherapy drug, a small molecule targeted anti-tumour drug or an immunotherapy drug. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.

A method of treating nervous system cancer or soft-tissue sarcoma in a subject is described. The method includes administering a therapeutically effective amount of a compound according to formula I to a subject in need thereof:wherein R1 is selected from the group consisting of —OH, —OAc, —OCHO, ═O, and ═NOH; R2 is selected from the group consisting of —CON(CH3)2, —CONHCH3, —CONH2, —COOCH3, —COOH, and —H, R3 is selected from the group consisting of —H, —OH, and —OCH3, and R4 is selected from the group consisting of —OH, —OCH3, —OCH2CH3.

Disclosed in the present application is the use of a compound of formula I in the preparation of a drug for treating the following tumors, which are selected from gastric cancer, esophageal cancer, cholangiocarcinoma, nasopharyngeal cancer, soft tissue sarcoma, prostate cancer, liver cancer, non-small cell lung cancer, breast cancer, glioma, leukemia, ovarian cancer, cervical cancer, endometrial carcinoma, primary brain tumors, brain metastatic tumors, pancreatic cancer and angiosarcoma. Further disclosed is the use of the compound in combination with other anti-tumor drugs in the treatment of the above-mentioned cancers.

The present invention relates to the treatment of soft tissue sarcomas and vascular tumors such as angiosarcoma, hemangiomas or hemangioendothelioma, using a halogenated heterocyclic kinase inhibitor. In particular, the invention relates to halogenated heterocyclic kinase inhibitor, optionally in combination with a second therapeutic for the treatment of soft tissue sarcomas or vascular tumors, such as angiosarcoma, hemangiomas or hemangioendotheliomas.

The present disclosure provides methods of treatment comprising anti-EDB antibodies and antibody-drug conjugates. The present disclosure further provides methods of treating EDB+ FN-expressing disorders, such as cancer. In some aspects, the cancer is selected from the group consisting of ER+HR+Her2-breast cancer, triple negative breast cancer (TNBC), head and neck cancer, hepatocellular carcinoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, renal cancer, soft tissue sarcoma (sarcoma), and thyroid cancer.

The present invention relates to pharmaceutical compositions and methods for the treatment of carcinomas and sarcomas. In particular, the invention provides a pharmaceutical composition comprising a peptide or pharmaceutically acceptable salt thereof for use in treating a carcinoma or a sarcoma in a human subject, wherein the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1 and a cell penetrating peptide and wherein the pharmaceutical composition is systemically administered to the subject weekly to provide a dose of the peptide of about 15-65 mg / m2 body surface area (BSA) per week, calculated as the free form of the peptide.

The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile and pharmaceutically acceptable salts and solvates thereof, that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and / or soft tissue sarcomas.

To provide use of a Mitoxantrone Hydrochloride liposome in the manufacture of a medicament for treating bone and soft tissue sarcomas.SOLUTION: Use of a Mitoxantrone Hydrochloride liposome in the manufacture of a medicament for the treatment of metastatic or locally advanced bone and soft tissue sarcomas that have failed at least first line therapy is provided.SELECTED DRAWING: None